These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31505070)

  • 1. Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
    Iwaki H; Blauwendraat C; Leonard HL; Kim JJ; Liu G; Maple-Grødem J; Corvol JC; Pihlstrøm L; van Nimwegen M; Hutten SJ; Nguyen KH; Rick J; Eberly S; Faghri F; Auinger P; Scott KM; Wijeyekoon R; Van Deerlin VM; Hernandez DG; Gibbs JR; ; Chitrala KN; Day-Williams AG; Brice A; Alves G; Noyce AJ; Tysnes OB; Evans JR; Breen DP; Estrada K; Wegel CE; Danjou F; Simon DK; Andreassen O; Ravina B; Toft M; Heutink P; Bloem BR; Weintraub D; Barker RA; Williams-Gray CH; van de Warrenburg BP; Van Hilten JJ; Scherzer CR; Singleton AB; Nalls MA
    Mov Disord; 2019 Dec; 34(12):1839-1850. PubMed ID: 31505070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
    Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
    JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occupational Pesticide Exposure in Parkinson's Disease Related to GBA and LRRK2 Variants.
    Brown EG; Goldman SM; Coffey CS; Siderowf A; Simuni T; Meng C; Brumm MC; Caspell-Garcia C; Marek K; Tanner CM;
    J Parkinsons Dis; 2024; 14(4):737-746. PubMed ID: 38820021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.
    Mata IF; Johnson CO; Leverenz JB; Weintraub D; Trojanowski JQ; Van Deerlin VM; Ritz B; Rausch R; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Peterson-Hiller AL; Espay AJ; Revilla FJ; Devoto J; Yearout D; Hu SC; Cholerton BA; Montine TJ; Edwards KL; Zabetian CP
    Neurobiol Aging; 2017 Aug; 56():211.e1-211.e7. PubMed ID: 28526295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of
    Malek N; Weil RS; Bresner C; Lawton MA; Grosset KA; Tan M; Bajaj N; Barker RA; Burn DJ; Foltynie T; Hardy J; Wood NW; Ben-Shlomo Y; Williams NW; Grosset DG; Morris HR;
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):702-709. PubMed ID: 29378790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.
    Mangone G; Bekadar S; Cormier-Dequaire F; Tahiri K; Welaratne A; Czernecki V; Pineau F; Karachi C; Castrioto A; Durif F; Tranchant C; Devos D; Thobois S; Meissner WG; Navarro MS; Cornu P; Lesage S; Brice A; Welter ML; Corvol JC;
    Parkinsonism Relat Disord; 2020 Jul; 76():56-62. PubMed ID: 32866938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.
    Winder-Rhodes SE; Evans JR; Ban M; Mason SL; Williams-Gray CH; Foltynie T; Duran R; Mencacci NE; Sawcer SJ; Barker RA
    Brain; 2013 Feb; 136(Pt 2):392-9. PubMed ID: 23413260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
    Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
    Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal.
    Berge-Seidl V; Pihlstrøm L; Maple-Grødem J; Forsgren L; Linder J; Larsen JP; Tysnes OB; Toft M
    Neurosci Lett; 2017 Sep; 658():48-52. PubMed ID: 28830825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals.
    Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P;
    Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.
    Szwedo AA; Dalen I; Pedersen KF; Camacho M; Bäckström D; Forsgren L; Tzoulis C; Winder-Rhodes S; Hudson G; Liu G; Scherzer CR; Lawson RA; Yarnall AJ; Williams-Gray CH; Macleod AD; Counsell CE; Tysnes OB; Alves G; Maple-Grødem J;
    Mov Disord; 2022 May; 37(5):1016-1027. PubMed ID: 35106798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
    da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
    J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).
    Nalls MA; Keller MF; Hernandez DG; Chen L; Stone DJ; Singleton AB;
    Mov Disord; 2016 Jan; 31(1):79-85. PubMed ID: 26268663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS
    Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinson's disease cohort.
    Graham OEE; Pitcher TL; Liau Y; Miller AL; Dalrymple-Alford JC; Anderson TJ; Kennedy MA
    Parkinsonism Relat Disord; 2020 Jan; 70():36-41. PubMed ID: 31809948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
    von Linstow CU; Gan-Or Z; Brundin P
    Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.